Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.71 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.52 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1335080 | 0.88 | RIPK2 (0.78) | RIPK2MAPK14RAB9ASMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL3517693 | 0.86 | RIPK2 (0.76) | RIPK2MAPK14RAB9ASMN1; SMN2POLB | |
| SCHEMBL3517691 | 0.85 | RIPK2 (0.73) | RIPK2MAPK14RAB9ALMNASMN1; SMN2 | |
| SCHEMBL24385178 | 0.85 | RIPK2 (0.73) | RIPK2MAPK14RAB9ALMNASMN1; SMN2 | |
| SCHEMBL8050439 | 0.84 | RIPK2 (0.72) | RIPK2MAPK14RAB9ALMNASMN1; SMN2 | |
| SCHEMBL8043230 | 0.84 | RIPK2 (0.72) | RIPK2MAPK14RAB9ALMNASMN1; SMN2 | |
| SCHEMBL8050422 | 0.84 | RIPK2 (0.71) | RIPK2MAPK14RAB9ALMNASMN1; SMN2 | |
| SCHEMBL13662120 | 0.83 | MAPK14 (1.00) | RIPK2MAPK14RAB9APOLBHPGD | |
| SCHEMBL4696735 | 0.83 | RIPK2 (0.71) | RIPK2MAPK14RAB9ALMNASMN1; SMN2 | |
| SCHEMBL2804588 | 0.83 | RIPK2 (0.71) | RIPK2MAPK14RAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | claimed |
| CN-101965350-A | Novel pyrazolo [3,4-d ] pyrimidine derivatives as anticancer agents | NATCO PHARMA LTD | 2011-02-02 | — | — | CN | claimed |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2010-11-25 | — | — | US | claimed |
| EP-2247596-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | Natco Pharma Limited (IN) | 2010-11-10 | — | — | EP | claimed |
| WO-2009098715-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-08-13 | — | — | WO | claimed |
| US-20250360134-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES | INST NAT SANTE RECH MED (FR) | 2025-11-27 | — | — | US | disclosed |
| EP-4263539-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE TREATMENT OF INFECTIOUS DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2023-10-25 | — | — | EP | disclosed |
| US-11772085-B2 | Far superior oxidation catalysts based on macrocyclic compounds | CARNEGIE MELLON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| EP-4100015-A1 | COMBINATION THERAPY FOR TREATING MPS1 | Gain Therapeutics SA (CH) | 2022-12-14 | — | — | EP | disclosed |
| CN-115397423-A | Combination therapy for the treatment of MPS1 | 增益治疗股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-1049682-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | Versicor, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| US-6074881-A | TEST FOR THE ACTIVITY OF A METAL CHELATE IN A FLUID SAMPLE; FOR THE DETECTION OF CREATININE IN A URINE SAMPLE | BAYER CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| EP-0978568-A2 | Method for the prevention of hemoglobin interference in reagent systems for measuring peroxidase activity | Bayer Corporation (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999037630-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | VERSICOR, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| US-4920119-A | XANTHINE OXIDASE INHIBITORS; CONTROL OR PREVENTION OF GOUT OR ISCHEMIA | HOFFMANN-LA ROCHE INC. (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0274654-A2 | 1,2,3-Triazin-4(3H)-one derivatives, process for their preparation and medicaments containing them | F. HOFFMANN-LA ROCHE AG (CH) | 1988-07-20 | — | — | EP | disclosed |
| US-4025622-A | ANTIBACTERIAL | Ogura, Haruo (JA) | 1977-05-24 | — | — | US | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | RIPK2 4695/4885MAPK14 4823/4885RAB9A 2497/4885 |
| US-11772085-B2 | Far superior oxidation catalysts based on macrocyclic compounds | SOD1, ME3, ME2 | RIPK2 4669/4885MAPK14 3283/4885RAB9A 1494/4885 |
| US-20250360134-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES | SARS1, CCR5, INTS6 | RIPK2 1464/4885MAPK14 4581/4885RAB9A 1882/4885 |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | DPYD, TYMP, TYMS | RIPK2 3763/4885MAPK14 992/4885RAB9A 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.